#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	4852	16S	1529	1529	99.93	16S.l15.c4.ctg.1	1929	418.1	0	.	n	.	0	C1450T	SNP	1450	1450	C	1667	1667	T	477	T,C	273,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	4852	16S	1529	1529	99.93	16S.l15.c4.ctg.1	1929	418.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1401	1401	C	469	C	274	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	9376	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3290	468.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1495	1495	A	506	A	299	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	9376	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3290	468.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2129	2129	C	434	C,G	249,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	9376	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3290	468.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2203	2203	A	436	A	251	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	9376	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3290	468.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	2755	2755	C	534	C	312	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	9376	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3290	468.4	0	HET	.	.	.	C265T,G	.	265	265	C	423	423	C	494	C,T,G	161,120,1	.	.
folP.WHO_G_01367c	folP.WHO_G_01367c	1	1	27	360	folP	852	852	100.0	folP.l6.c4.ctg.1	1608	38.4	1	SNP	p	R228S	1	.	.	682	684	AGC	1076	1078	AGC	75;75;75	A;G;C	46;45;44	folP.WHO_G_01367c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	1	1086	gyrA	2751	2289	100.0	gyrA.l15.c4.ctg.1	2445	65.0	1	SNP	p	S91F	0	.	.	271	273	TCC	427	429	TCC	87;89;88	T;C;C	55;54;52	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	1	1086	gyrA	2751	2289	100.0	gyrA.l15.c4.ctg.1	2445	65.0	1	SNP	p	D95G	0	.	.	283	285	GAC	439	441	GAC	93;94;95	G;A;C	54;56;58	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	1	1086	gyrA	2751	2289	100.0	gyrA.l15.c4.ctg.1	2445	65.0	1	SNP	p	D95N	0	.	.	283	285	GAC	439	441	GAC	93;94;95	G;A;C	54;56;58	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	1	1086	gyrA	2751	350	100.0	gyrA.l15.c4.ctg.2	563	43.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	248	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1046	37.7	0	.	p	.	0	A39T	NONSYN	115	117	GCC	323	325	ACC	52;53;53	A;C;C	32;32;34	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	248	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1046	37.7	0	.	p	.	0	R44H	NONSYN	130	132	CGC	338	340	CAC	54;54;54	C;A;C	34;34;34	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	248	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1046	37.7	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	521	523	CAC	66;64;63	C;A;C	37;34;37	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	248	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1046	37.7	1	SNP	p	G45D	0	.	.	133	135	GGC	341	343	GGC	54;54;54	G;G;C	34;34;33	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	184	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c17.ctg.1	751	42.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	783	906	parC	2304	2304	99.74	parC.l6.c4.ctg.1	2724	54.4	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1458	1460	GCA	42;42;42	G;C;A	25;24;24	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	783	906	parC	2304	2304	99.74	parC.l6.c4.ctg.1	2724	54.4	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	1941	1943	ATT	71;71;71	A;T;T	40;40;41	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	783	906	parC	2304	2304	99.74	parC.l6.c4.ctg.1	2724	54.4	1	SNP	p	D86N	0	.	.	256	258	GAC	411	413	GAC	72;72;72	G;A,G;C,A	44;43,2;44,2	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	783	906	parC	2304	2304	99.74	parC.l6.c4.ctg.1	2724	54.4	1	SNP	p	S87I	0	.	.	259	261	AGT	414	416	AGT	72;72;71	A,C;G;T	42,1;42;41	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	783	906	parC	2304	2304	99.74	parC.l6.c4.ctg.1	2724	54.4	1	SNP	p	S87R	0	.	.	259	261	AGT	414	416	AGT	72;72;71	A,C;G;T	42,1;42;41	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	783	906	parC	2304	2304	99.74	parC.l6.c4.ctg.1	2724	54.4	1	SNP	p	S87W	0	.	.	259	261	AGT	414	416	AGT	72;72;71	A,C;G;T	42,1;42;41	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	783	906	parC	2304	2304	99.74	parC.l6.c4.ctg.1	2724	54.4	1	SNP	p	S88P	0	.	.	262	264	TCC	417	419	TCC	72;71;68	T;C;C	44;43;40	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	783	906	parC	2304	257	91.14	parC.l6.c4.ctg.2	493	1.8	0	.	p	.	0	R51G	NONSYN	151	153	CGC	363	365	CCC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	783	906	parC	2304	257	91.14	parC.l6.c4.ctg.2	493	1.8	0	.	p	.	0	I52L	NONSYN	154	156	ATT	360	362	GGC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	783	906	parC	2304	257	91.14	parC.l6.c4.ctg.2	493	1.8	0	.	p	.	0	T62K	NONSYN	184	186	ACG	330	332	TCA	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	783	906	parC	2304	257	91.14	parC.l6.c4.ctg.2	493	1.8	0	.	p	.	0	A65G	NONSYN	193	195	GCG	321	323	CCC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	783	906	parC	2304	257	91.14	parC.l6.c4.ctg.2	493	1.8	0	.	p	.	0	P67fs	FSHIFT	199	199	C	157	157	C	ND	ND	ND	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	842	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2538	55.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1365	1367	GGC	52;53;53	G;G;C	35;34;31	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.15.001	penA.15.001	1	1	27	878	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2119	70.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1121	1123	GCA	106;105;107	G;C;A	64;62;65	penA.15.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	878	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2119	70.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1124	1126	ATC	109;108;108	A;T,A;C	63;65,1;66	penA.15.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	878	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2119	70.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1136	1138	GTG	114;114;114	G;T;G,T	67;65;68,1	penA.15.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	878	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2119	70.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1136	1138	GTG	114;114;114	G;T;G,T	67;65;68,1	penA.15.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	878	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2119	70.5	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1637	1639	ACC	54;54;52	A;C;C	31;33;35	penA.15.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	878	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2119	70.5	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1691	1693	GCG	35;34;35	G;C;G	23;22;21	penA.15.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	878	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2119	70.5	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1691	1693	GCG	35;34;35	G;C;G	23;22;21	penA.15.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	878	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2119	70.5	1	SNP	p	G542S	0	.	.	1624	1626	GGC	1814	1816	GGC	48;50;50	G;G;C	30;33;31	penA.15.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	878	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2119	70.5	1	SNP	p	G545S	0	.	.	1633	1635	GGC	1823	1825	GGC	44;44;44	G;G;C	30;31;28	penA.15.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	878	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2119	70.5	1	SNP	p	P551S	0	.	.	1651	1653	CCG	1841	1843	CCG	44;44;44	C;C;G	24;25;25	penA.15.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1494	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3239	70.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	414	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1563	44.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	447	447	C	32	C	19	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	96.47	porB1b.l6.c4.ctg.1	1401	64.4	0	.	p	.	0	E48G	NONSYN	142	144	GAA	314	316	GGA	95;94;94	G;G;A	51;52;51	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	96.47	porB1b.l6.c4.ctg.1	1401	64.4	0	.	p	.	0	F135L	NONSYN	403	405	TTT	575	577	CTT	46;46;49	C;T;T	30;28;32	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	96.47	porB1b.l6.c4.ctg.1	1401	64.4	0	.	p	.	0	R143G	NONSYN	427	429	AGA	599	601	GGA	43;43;43	G;G;A	27;25;24	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	96.47	porB1b.l6.c4.ctg.1	1401	64.4	0	.	p	.	0	G189S	NONSYN	565	567	GGC	737	739	AGC	74;74;74	A;G;C	45;44;45	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	96.47	porB1b.l6.c4.ctg.1	1401	64.4	0	.	p	.	0	Y211_N212insDGQ	INS	631	631	T	803	803	T	98	T	58	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	96.47	porB1b.l6.c4.ctg.1	1401	64.4	0	.	p	.	0	N212_S213insL	INS	634	634	A	816	816	C	100	C	60	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	96.47	porB1b.l6.c4.ctg.1	1401	64.4	0	.	p	.	0	I214M	NONSYN	640	642	ATC	824	826	ATG	89;91;92	A;T;G	50;52;54	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	96.47	porB1b.l6.c4.ctg.1	1401	64.4	0	.	p	.	0	L218F	NONSYN	652	654	CTT	836	838	TTT	99;100;99	T;T;T	54;59;57	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	96.47	porB1b.l6.c4.ctg.1	1401	64.4	0	.	p	.	0	A238V	NONSYN	712	714	GCC	896	898	GTT	112;110;110	G;T;T	64;62;62	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	96.47	porB1b.l6.c4.ctg.1	1401	64.4	0	.	p	.	0	T252A	NONSYN	754	756	ACA	938	940	GCA	83;83;76	G;C;A	49;51;47	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	96.47	porB1b.l6.c4.ctg.1	1401	64.4	0	.	p	.	0	W253T	NONSYN	757	759	TGG	941	943	ACG	75;75;75	A;C;G,T	47;46;44,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	96.47	porB1b.l6.c4.ctg.1	1401	64.4	0	.	p	.	0	S254R	NONSYN	760	762	AGT	944	946	AGG	74;69;71	A;G;G	44;40;42	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	96.47	porB1b.l6.c4.ctg.1	1401	64.4	0	.	p	.	0	A255V	NONSYN	763	765	GCT	947	949	GTT	71;71;71	G;T;T	42;42;41	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	96.47	porB1b.l6.c4.ctg.1	1401	64.4	0	.	p	.	0	L275V	NONSYN	823	825	TTA	1007	1009	GTA	67;67;67	G;T;A	42;42;41	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	96.47	porB1b.l6.c4.ctg.1	1401	64.4	0	.	p	.	0	S288T	NONSYN	862	864	TCT	1046	1048	ACT	63;69;69	A;C;T	40;44;43	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	96.47	porB1b.l6.c4.ctg.1	1401	64.4	0	.	p	.	0	H290N	NONSYN	868	870	CAT	1052	1054	AAT	73;73;73	A;A;T	47;46;46	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	96.47	porB1b.l6.c4.ctg.1	1401	64.4	0	.	p	.	0	S291D	NONSYN	871	873	AGT	1055	1057	GAT	75;73;70	G;A;T	47;45;43	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	96.47	porB1b.l6.c4.ctg.1	1401	64.4	0	.	p	.	0	D293N	NONSYN	877	879	GAC	1061	1063	AAC	65;65;65	A;A;C	41;40;40	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	96.47	porB1b.l6.c4.ctg.1	1401	64.4	0	.	p	.	0	Y294H	NONSYN	880	882	TAC	1064	1066	CAC	64;64;64	C;A,C;C	40;39,1;39	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	96.47	porB1b.l6.c4.ctg.1	1401	64.4	0	.	p	.	0	E329D	NONSYN	985	987	GAA	1169	1171	GAC	83;83;83	G;A;C	50;50;51	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	96.47	porB1b.l6.c4.ctg.1	1401	64.4	1	SNP	p	G120K	0	.	.	358	360	GGT	530	532	GGT	52;54;54	G;G;T	32;35;34	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	96.47	porB1b.l6.c4.ctg.1	1401	64.4	1	SNP	p	A121D	0	.	.	361	363	GCC	533	535	GCC	54;54;54	G;C;C	31;32;30	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	96.47	porB1b.l6.c4.ctg.1	1401	64.4	1	SNP	p	A121N	0	.	.	361	363	GCC	533	535	GCC	54;54;54	G;C;C	31;32;30	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	527	2614	rpoB	4179	4179	99.98	rpoB.l15.c17.ctg.1	4518	96.3	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1810	1812	CAT	86;86;86	C;A;T	56;54;55	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	527	2614	rpoB	4179	386	99.48	rpoB.l15.c17.ctg.2	429	9.5	0	.	p	.	0	N20fs	FSHIFT	58	58	A	100	100	A	1	A	1	.	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	258	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	929	52.8	1	SNP	p	V57M	0	.	.	169	171	GTG	441	443	GTG	102;97;100	G;T;G	65;64;62	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
